Stockreport

Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

Natera, Inc.  (NTRA) 
Last natera, inc. earnings: 2/26 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.natera.com
PDF First-of-its-kind study in gastroesophageal adenocarcinoma using Signatera to guide treatment and assess the efficacy of a novel HER2-directed adjuvant treatment AUST [Read more]